Reviewer's report

**Title:** Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib.

**Version:** 1  **Date:** 7 June 2012

**Reviewer:** Steven K. Feske

**Reviewer's report:**

This is a straightforward case report of a patient who suffered an episode of posterior reversible encephalopathy syndrome associated with the use of pazopanib. Although it is well known that this occurs with this class of vasoactive agents, to my knowledge, this is the first report of PRES with pazopanib. On that basis, it merits publication.

**Major Compulsory Revisions**

1. There are minor problems with English language syntax and style. These need to be revised with the assistance of an editor before publication.

**Minor Essential Revisions**


2. Page 6, line 2: Clarify meaning of "performance status of the patient was 1."

3. Page 7, line 7: There is no need to use (ADR) or other abbreviations for single-use mention, especially when abbreviations are not well known.

4. Page 7, line 14: Reference 12 citation should follow the sentence ending in "usage."

5. Page 8, line 9: A modest increase in BP, even acute, should not lead to focal cerebral edema unless there is some underlying endothelial dysfunction, as for example caused by eclampsia or drugs.

6. Page 8, next sentence: The hypothesis concerning the posterior predilection for PRES changes is stated twice redundantly. Eliminate one statement. Also, this should be offered as an hypothesis and not asserted as a fact.

7. Page 9, last paragraph before the CONCLUSION: Delete this paragraph. Although it is important to the patient's care, it is off message for this focused case report.

**Discretionary Revisions**

Figure: The slices for 2B, 2D, and 2F are higher than for 1B, 1D, and 1F. That
might have been unavoidable if there was no more nearly equivalent slice. But if there was, then it should be changed.

**Level of interest:** An article of importance in its field

**Quality of written English:** Not suitable for publication unless extensively edited

**Statistical review:** No, the manuscript does not need to be seen by a statistician.